Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBM-H901 in Adolescent Hemophilia B
NCT05709288Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2023
- Primary completion
- Jun 2035
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalnacogene ponparvovec in hemophilia B (HB), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Incidence of treatment related adverse events deemed related to BBM-H901 at 10 weeks, Incidence of adverse events and serious adverse events at 52 weeks and 2 more. Started Mar 2023; status: recruiting.
02
Drugs
dalnacogene ponparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT05709288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05709288.